SS-31: Research & Studies

Research Overview#

SS-31 (elamipretide) is among the most extensively studied mitochondria-targeted peptides, with a clinical development program spanning multiple Phase 2 and Phase 3 trials. The research evidence base ranges from foundational preclinical studies establishing the cardiolipin binding mechanism to pivotal clinical trials in Barth syndrome and investigational studies in heart failure and primary mitochondrial myopathy. While the overall evidence level is moderate, the strength of the preclinical rationale and the breadth of clinical investigation distinguish SS-31 from most other mitochondrial-targeted agents.

Preclinical Foundation#

Cardiolipin Binding and ETC Optimization#

The mechanistic foundation of SS-31 research was established through a series of biochemical and cell biology studies demonstrating the peptide's selective binding to cardiolipin and consequent stabilization of electron transport chain supercomplexes. Key preclinical findings include the demonstration that SS-31 binds cardiolipin with high selectivity over other phospholipids, concentrates more than 1,000-fold within the inner mitochondrial membrane, restores ETC supercomplex formation in aged and diseased mitochondria, reduces mitochondrial ROS production by improving electron transfer efficiency, and inhibits the peroxidase activity of the cardiolipin-cytochrome c complex.

These findings shifted the understanding of SS-31 from a simple mitochondrial antioxidant to a cardiolipin-stabilizing agent that optimizes mitochondrial bioenergetics. This mechanistic reframing was critical for the selection of Barth syndrome, a disease of defective cardiolipin remodeling, as the lead clinical indication.

Aging and Organ Protection Models#

Preclinical studies of SS-31 in aging models generated substantial interest in the peptide as a potential geroprotective agent. In aged mice, SS-31 treatment reversed age-related decline in mitochondrial function in the heart, restoring cardiac diastolic function to levels comparable to young animals. Similar findings were reported in aged skeletal muscle, where SS-31 restored mitochondrial ATP production, improved exercise tolerance, and reduced oxidative damage markers.

In kidney and brain aging models, SS-31 similarly ameliorated age-related pathology, establishing that mitochondrial dysfunction across multiple organ systems is amenable to pharmacological intervention through cardiolipin stabilization. In ischemia-reperfusion injury models, SS-31 demonstrated robust cardioprotection when administered at the time of reperfusion, reducing infarct size and preserving left ventricular function. These findings provided the preclinical rationale for the EMBRACE STEMI trial.

TAZPOWER Trial: Barth Syndrome#

Study Design#

The TAZPOWER trial was the pivotal Phase 3 study for elamipretide in Barth syndrome. The trial used a randomized, double-blind, placebo-controlled crossover design, enrolling 12 patients with genetically confirmed Barth syndrome (mutations in the tafazzin gene). Each patient received both elamipretide (40 mg subcutaneous injection daily) and matching placebo in two 12-week treatment periods, with the order randomized. The primary efficacy endpoint was the change in six-minute walk test (6MWT) distance.

Results and Interpretation#

The TAZPOWER trial demonstrated trends toward improvement in 6MWT distance with elamipretide treatment, but the primary endpoint did not achieve conventional statistical significance (p < 0.05). This result must be interpreted in the context of the extraordinary challenges of conducting a rigorous clinical trial in an ultra-rare disease that affects fewer than one in 300,000 to 400,000 individuals. The sample size of 12 patients, while representing a substantial proportion of the known Barth syndrome population, provides limited statistical power to detect moderate effect sizes.

The trial did report statistically significant improvements on certain secondary endpoints, notably the five-times sit-to-stand test, which measures lower extremity strength and functional mobility. This finding was consistent with the expected bioenergetic benefit of cardiolipin stabilization in skeletal muscle.

Open-Label Extension#

Open-label extension data provided additional context for interpreting the TAZPOWER results. Patients who continued on elamipretide in the extension study demonstrated sustained improvements in functional measures over periods extending to years of treatment. These uncontrolled data are subject to the limitations inherent in open-label studies, including placebo effects and natural disease course variability, but they supported the biological plausibility of sustained benefit with chronic treatment.

Regulatory Outcome#

Stealth BioTherapeutics submitted a New Drug Application (NDA) to the FDA based on the TAZPOWER trial data and open-label extension results. The FDA issued a Complete Response Letter (CRL), indicating that the submitted data package was insufficient to support approval and requesting additional data. The CRL reflected the regulatory challenge of demonstrating efficacy in ultra-rare diseases where small sample sizes limit the statistical power of conventional trial designs. The development program has continued under Larimar Therapeutics, which acquired the elamipretide assets.

EMBRACE STEMI Trial#

Study Design#

The EMBRACE STEMI trial was a Phase 2a, randomized, double-blind, placebo-controlled study evaluating a single intravenous dose of elamipretide (0.25 mg/kg) in patients presenting with first-time ST-elevation myocardial infarction and undergoing percutaneous coronary intervention. The primary endpoint was the area under the curve (AUC) of creatine kinase-MB (CK-MB) release, a biomarker of myocardial necrosis. Secondary endpoints included infarct size by cardiac MRI.

Results#

The EMBRACE trial did not meet its primary CK-MB endpoint, with no statistically significant reduction in CK-MB AUC in the elamipretide group compared to placebo. However, cardiac MRI results demonstrated trends toward reduced infarct size in the treatment group, suggesting a potential cardioprotective effect that was not captured by the enzymatic biomarker endpoint.

The discordance between CK-MB and MRI findings may reflect differences in the sensitivity and specificity of these endpoints for detecting the type of mitochondrial protection provided by SS-31. CK-MB release is an early, nonspecific marker of myocardial injury that may be influenced by factors beyond mitochondrial function, while cardiac MRI provides a more direct assessment of salvaged myocardium.

Implications#

Despite failing its primary endpoint, the EMBRACE trial contributed important translational evidence. It demonstrated the feasibility and safety of IV elamipretide administration in the acute coronary care setting and provided imaging data consistent with cardioprotection. The results informed the understanding that mitochondrial protection during reperfusion may require refinement in dose, timing, or patient selection to achieve statistically demonstrable clinical benefit.

Heart Failure with Reduced Ejection Fraction#

The Phase 2 trial in HFrEF evaluated 4 weeks of subcutaneous elamipretide (40 mg daily) and demonstrated improvements in left ventricular end-systolic volume, a measure of cardiac remodeling. Trends toward improved cardiac output were also observed. These findings supported the hypothesis that mitochondrial dysfunction contributes to heart failure pathophysiology and that targeting cardiolipin can produce measurable improvements in cardiac function.

The HFrEF results demonstrated that a relatively short course of elamipretide could produce detectable cardiac reverse remodeling. No Phase 3 trial in heart failure has been initiated, and the indication has not advanced beyond Phase 2.

Primary Mitochondrial Myopathy#

The Phase 2 PMM trial evaluated 5 days of IV elamipretide (0.25 mg/kg daily) in patients with genetically confirmed primary mitochondrial myopathy. Numerical improvements in 6MWT distance were observed, but the short treatment duration and genetically heterogeneous patient population limited interpretability. Longer treatment durations would be needed to demonstrate definitive efficacy.

Evidence Level Assessment and Research Gaps#

The overall evidence level for SS-31 is classified as moderate. Strengths include a well-characterized molecular mechanism, multiple completed clinical trials, a Phase 3 trial in Barth syndrome, consistent safety, and clear biological rationale linking cardiolipin stabilization to the target disease. Limitations include the failure to meet primary endpoints in both TAZPOWER and EMBRACE, small sample sizes, no Phase 3 data outside Barth syndrome, and the FDA Complete Response Letter. Key research gaps include the absence of a large-scale heart failure outcomes trial, lack of formal dose-ranging studies for non-Barth indications, incomplete biomarker development, regulatory uncertainty following the CRL, and the absence of clinical translation of preclinical aging data.

Related Reading#

• SS-31 overview and research guide
• SS-31 dosing protocols
• SS-31 molecular structure